Treatment of SREAT (Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis)
Start high-dose intravenous methylprednisolone (1 gram daily for 3-5 days) immediately after ruling out infection, followed by a prolonged oral prednisone taper over 13 weeks or longer. 1
First-Line Treatment Algorithm
SREAT is explicitly recognized as a steroid-responsive condition in autoimmune encephalitis guidelines, and corticosteroids are the definitive first-line therapy 1. The treatment approach follows this sequence:
Acute Phase
- Initiate high-dose IV methylprednisolone once infection is excluded based on CSF cell count and basic studies 1
- Standard dosing: 1 gram IV daily for 3-5 days 2, 3, 4
- Clinical improvement typically occurs rapidly, often within days of starting treatment 2, 3
Maintenance Phase
- Transition to oral prednisone taper lasting 13 weeks minimum 2
- Alternative bridging options include monthly IV methylprednisolone or monthly IVIG 1
- The prolonged taper is critical to prevent relapse
When First-Line Therapy Fails
If no clinical improvement occurs after completing the initial steroid course:
Add Second-Line Agents
IVIG should be added first in most cases 1
- Preferred for agitated patients
- Preferred if bleeding disorders present
Plasma exchange (PLEX) as alternative 1
- 5-10 sessions every other day
- Consider first if severe hyponatremia present
- Consider first if high thromboembolic risk
Escalation to Immunosuppression
If no improvement 2-4 weeks after combined first-line therapy 1:
- Rituximab is the preferred second-line agent for antibody-mediated autoimmunity 1
- Less toxic than cyclophosphamide
- Cyclophosphamide reserved for suspected cell-mediated disease 1
Critical Diagnostic Considerations
Before initiating steroids, you must:
- Rule out infection via CSF analysis (cell count, protein, glucose) 1
- Exclude CNS lymphoma if clinically suspected (biopsy may be needed) 1
- Confirm elevated antithyroid antibodies (anti-TPO and/or anti-thyroglobulin) 2, 3, 4
- Note: Thyroid function tests may be normal; euthyroid state does not exclude SREAT 3, 5
Common Pitfalls to Avoid
Do not delay treatment waiting for antibody results if clinical suspicion is high and infection is ruled out. SREAT can present with super-refractory status epilepticus requiring immediate intervention 4.
Do not stop steroids prematurely. The recent case literature consistently demonstrates that a 13-week taper is necessary 2. Shorter courses risk relapse.
Do not be misled by normal thyroid function. Patients can be euthyroid and still have SREAT 3, 5. The diagnosis depends on elevated antithyroid antibodies, not thyroid dysfunction.
Do not dismiss atypical presentations. SREAT can present with CSF pleocytosis, leptomeningeal enhancement, and complex comorbidities that obscure the diagnosis 5. Maintain suspicion even with atypical features.
In geriatric patients with new neuropsychiatric symptoms, SREAT is a must-not-miss, reversible diagnosis 2. Hospital-acquired delirium can cloud the clinical picture but should not delay consideration of SREAT.
Monitoring Response
Expect rapid improvement within days to weeks of starting high-dose steroids 2, 3, 4. Full neurological recovery and sustained seizure freedom have been documented at 3-month follow-up with appropriate treatment 4. The dramatic response to corticosteroids is both diagnostic and therapeutic.